Lake Street Lowers Tela Bio Price Target to $3 Amid Q3 Results Shortfall
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Lake Street lowered the firm's price target on Tela Bio to $3 from $6 and keeps a Buy rating on the shares following Q3 results that "were short of the Street" and 2025 and 2026 guidance that was down on prolonged sales force disruption. The firm believes shares could be range bound in the near-term, but also thinks the recapped balance sheet and reset outlook will "provide the team an opportunity to exceed expectations," the analyst tells investors.
Analyst Views on TELA
Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is 3.31 USD with a low forecast of 1.25 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.980
Low
1.25
Averages
3.31
High
5.00
Current: 0.980
Low
1.25
Averages
3.31
High
5.00
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
